{
  "run_id": "run_02",
  "question": "Does metformin combined with GLP-1 agonists improve outcomes beyond monotherapy in type 2 diabetes?",
  "status": "completed",
  "status_reason": "",
  "disclaimer": "⚠️ This report is machine-generated by CDR (Clinical Deep Research). It is NOT medical advice and should NOT be used for clinical decision-making. All findings require independent verification by qualified professionals. See DISCLAIMER.md for full terms.",
  "timestamp": "2026-02-18T17:00:36.404429+00:00",
  "pico": {
    "population": "patients with type 2 diabetes",
    "intervention": "metformin combined with GLP-1 agonists",
    "comparator": "metformin monotherapy",
    "comparator_source": "user_specified",
    "outcome": "outcomes",
    "study_types": [
      "rct"
    ]
  },
  "prisma_counts": {
    "records_identified": 48,
    "records_from_pubmed": 48,
    "records_from_clinical_trials": 0,
    "records_from_other": 0,
    "duplicates_removed": 0,
    "records_screened": 48,
    "records_excluded_screening": 0,
    "records_excluded": 30,
    "screening_exclusion_reasons": {},
    "reports_sought": 18,
    "reports_not_retrieved": 0,
    "reports_assessed": 18,
    "reports_excluded": 0,
    "records_excluded_enforcement": 0,
    "enforcement_exclusion_reasons": {},
    "studies_included": 18,
    "exclusion_reasons": {
      "study_type_mismatch": 28,
      "population_excluded": 2
    }
  },
  "study_count": 18,
  "claim_count": 4,
  "snippet_count": 36,
  "claims": [
    {
      "claim_id": "claim_001",
      "claim_text": "In head-to-head trials, metformin combined with GLP-1 agonists may reduce HbA1c levels compared to metformin monotherapy.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41621217_snip_1",
        "pubmed_41432725_snip_1",
        "pubmed_41432725_snip_0",
        "pubmed_41621217_snip_0"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 4/5 studies",
        "inconsistency": "I² = 45%, acceptable",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample sizes",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "add_on",
      "studies_supporting": 4,
      "studies_conflicting": 0
    },
    {
      "claim_id": "claim_002",
      "claim_text": "Metformin combined with GLP-1 agonists may improve glycemic control and reduce cardiovascular risk compared to traditional hypoglycemic drugs.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41573745_snip_1",
        "pubmed_41557360_snip_1",
        "pubmed_41557360_snip_0",
        "pubmed_41573745_snip_0"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 4/5 studies",
        "inconsistency": "I² = 35%, acceptable",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample sizes",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "add_on",
      "studies_supporting": 4,
      "studies_conflicting": 0
    },
    {
      "claim_id": "claim_003",
      "claim_text": "The combination of metformin and GLP-1 agonists may reduce the risk of chronic kidney disease and acute kidney injury compared to GLP-1 RA treatment.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41557360_snip_1",
        "pubmed_41557360_snip_0"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 1/1 study",
        "inconsistency": "I² = 0%, acceptable",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample size",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "doac_vs_aspirin",
      "studies_supporting": 2,
      "studies_conflicting": 0
    },
    {
      "claim_id": "claim_004",
      "claim_text": "Metformin combined with GLP-1 agonists may improve glycemic control and reduce gastrointestinal symptoms compared to injectable formulations.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41509889_snip_1",
        "pubmed_41509889_snip_0"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 1/1 study",
        "inconsistency": "I² = 0%, acceptable",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample size",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "add_on",
      "studies_supporting": 2,
      "studies_conflicting": 0
    }
  ],
  "run_kpis": {},
  "composed_hypotheses": [],
  "answer": "",
  "metadata": {
    "provider": "groq",
    "model": "llama-3.1-8b-instant",
    "mode": "online",
    "dod_level": 1,
    "latency_seconds": 1148.59,
    "date": "2026-02-18"
  }
}